Figure 1



1 MEHQLLCCEV ETIRRAYPDA NLLNDRVLRA MLKAEETCAP SVSYFKCVQK EVLPSMRKIV
CCN-E
CCN-I
61 ATWMLEVCEE QKCEEEVFPL AMNYLDRFLS LEPVKKSRLQ LLGATCMFVA SKMKETIPLT
CCN-A
CCN-004 AND F1 TO F3
CCN-001
CCN-006
121 AEKLCIYTDN SIRPEELLQM ELLLVNKLKW NLAAMTPHDF IEHFLSKMPE AEENKQIIRK
CCN-H
CCN-J
181 HAQTFVALCA TDVKFISNPP SMVAAGSVVA AVQGLNLRSP NNFLSYYRLT RFLSRVIKCD
CCN-003
CCN-B TO D AND G
CCN-002
241 PDCLRACQEQ IEALLESSLR QAQQNMDPKA AEEEEEEEEE VDLACTPTDV RDVDI
CCN-007

Figure 2 - Expression data




Figure 2 continued





Figure 3

A



B





Figure 4

A


Estimated Survival Probability (%)
100
90
80
70
60
50
40
30
20
10
0
3
6
9
12
15
18
21
24
Time (months)
vaccine plus Cy
Median
Trial 1: 16.4 months
(95% CI, 10.8 to NA)

B




Probability of Survival (%)
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
14
16
18
20
22
24
Months
IMA901 plus Cy
IMA901
Sorafenib
Placebo

Figure 5

A


Absolute Treg and lymphocyte counts
(medians)
TREGS / +CY
TREGS / -CY
Lymphocytes / +CY
Lymphocytes / -CY
absolute Tregs [1/µL]
absolute lymphocytes [x10^9/L]
35
30
25
20
2,0
1,8
1,6
1,4
1,2
1,0
VB
VC
V1
V6

B




Absolute Treg counts
(% change from baseline - medians)
TREGS / +CY
TREGS / -CY
% change from baseline
20%
10%
0%
-10%
-20%
-30%
*
VC
V1
V6

Figure 6

A (All patients)



B (Cyclophosphamide pretreated patients)





Figure 7


A
CCN-001
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
% pts responding
Cohort 1
Cohort 2
Total
B
HLA-A*0201/CCN-001
CD8
HLA-A*0201/CCN-001
CD8